OmniAb, Inc. (OABI) Stock

Understand OmniAb, Inc.: how it makes money

OmniAb licenses antibody repertoires from its genetically modified animals (OmniRat, OmniChicken, OmniMouse) to pharmaceutical partners, earning upfront fees, clinical milestones, and eventual product royalties. The model is lumpy and milestone-driven, with cash flowing in step with each partner's program advancing through development rather than as steady recurring fees.

Each licensed antibody carries near-zero marginal cost for OmniAb, then generates step-up milestone payments as the partner's program hits each clinical gate, culminating in perpetual royalties once a drug sells commercially.

Business quality (Weak): A pre-profit platform with a strong pipeline (32 programs in trials) and top-tier pharma partners, but revenue is still negligible and the company is burning cash well before royalties scale.

Bull case

• Milestone backlog underwrites future revenue: Management cited $340 million of remaining contracted potential milestones across active clinical programs, giving tangible revenue visibility well beyond the current near-zero top line if those programs advance.
• Top-10 pharma validates the platform: Eight of the ten largest pharmaceutical companies remain active OmniAb partners, a peer-level endorsement that the transgenic-animal antibody model works at the most demanding R&D standard in the industry.

Bear case

• Cash runway is narrowing: Management expects year-end cash to fall below the $52 million Q2 balance while the company operates at a -50% operating margin, implying another dilutive financing if clinical milestones do not arrive on schedule.
• Royalties are still theoretical: The long-term royalty model only becomes meaningful once partner programs complete clinical development and reach the market; until then the company depends on a handful of lumpy milestone payments to fund operations.
• Revenue lumps create planning risk: Quarterly revenue is volatile because milestone payments arrive in uneven bursts tied to partner trial readouts, making it difficult for investors to model steady cash generation in the near term.

OmniAb, Inc. earnings call transcripts

• OABI Q2 FY26 earnings call transcript (reported 2026-08-06) · analysis
• OABI Q1 FY26 earnings call transcript (reported 2026-05-07) · analysis

All OABI earnings calls

Related Companies (Business Services; 8 comparable business services companies)

• bioAffinity Technologies, Inc. (BIAF)
• Absci Corporation (ABSI)
• National Research Corporation (NRC)
• iSpecimen Inc. (ISPC)
• ImmuCell Corporation (ICCC)
• American Shared Hospital Services (AMS)
• OneMedNet Corporation (ONMD)
• Alpha Teknova, Inc. (TKNO)